Ebola

Opinion: I led the CDC response to the 2014 Ebola epidemic. The new outbreak needs massive

Former CDC Director Tom Frieden argues that the new Ebola outbreak demands a massive, immediate, and meticulous response. This article provides a structured analysis for pharma strategy and BD teams on the implications and required actions.

CDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures

A new CDC analysis warns the Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures. This article examines the modeling, current case counts, and implications for pharma teams.

Ebola 2026: US Response and Travel Restrictions Debate

The 2026 Ebola outbreak has reignited debate over US travel restrictions and the right of American healthcare workers to return home. This article examines the policy, public health, and industry implications.

HHS Confirms Americans with High-Risk Ebola Exposures Will Have Access to Experimental Therapy MBP-134

HHS has confirmed that Americans with high-risk Ebola exposures in the current Central African outbreak will have access to the experimental monoclonal antibody treatment MBP-134 from Mapp Biopharmaceuticals. This decision, based on promising animal data, signals a potential shift in emergency use policy and creates competitive benchmarking opportunities for pharma teams.

Kenya Court Halts U.S. Ebola Quarantine Facility Plans: Pharma Sector Analysis

A Kenyan High Court has suspended a U.S. plan to build an Ebola quarantine facility for Americans, raising new risks for pharma companies operating in Africa. The decision highlights the need for stronger local regulatory engagement and community-focused access strategies.

Ebola Response Shift: Trump Administration's New Playbook and Pharma Implications

The Trump administration's revised approach to the Ebola outbreak signals a departure from established protocols, creating new dynamics for pharmaceutical companies. This shift necessitates a strategic reassessment of vaccine and treatment development, regulatory engagement, and market positioning.

NIH Funding Cuts Hamper Ebola Preparedness and Global Health Security

Recent cuts to the National Institutes of Health (NIH) have significantly weakened the network established to respond to infectious disease outbreaks, including Ebola. This reduction in funding and infrastructure compromises the United States' and global capacity to effectively manage future health crises.

STAT+ Pharmalittle: Lilly's 340B Hospital Threat, Ebola Vaccine Funding, and More

STAT+ Pharmalittle reports on Eli Lilly's ultimatum to 340B hospitals regarding claims data submission and the latest developments in Ebola vaccine funding. This news roundup highlights critical shifts in pharmaceutical access and global health initiatives.